TY - JOUR
T1 - Comparison Between Thulium Fiber Laser and High-power Holmium Laser for Anatomic Endoscopic Enucleation of the Prostate
T2 - A Propensity Score–matched Analysis from the REAP Registry
AU - Gauhar, Vineet
AU - Nedbal, Carlotta
AU - Castellani, Daniele
AU - Fong, Khi Yung
AU - Sofer, Mario
AU - Socarrás, Moisés Rodríguez
AU - Tursunkulov, Azimdjon N.
AU - Ying, Lie Kwok
AU - Elterman, Dean
AU - Mahajan, Abhay
AU - Petov, Vladislav
AU - Ivanovich, Sorokin Nikolai
AU - Bhatia, Tanuj Paul
AU - Enikeev, Dmitry
AU - Gadzhiev, Nariman
AU - Chiruvella, Mallikarjuna
AU - Teoh, Jeremy Yuen Chun
AU - Galosi, Andrea Benedetto
AU - Sancha, Fernando Gómez
AU - Somani, Bhaskar Kumar
AU - Herrmann, Thomas R.W.
N1 - Publisher Copyright:
© 2023 European Association of Urology
PY - 2024/1
Y1 - 2024/1
N2 - Background: Different lasers have been developed for treatment of benign prostatic hyperplasia, with no definitively superior technique identified to date. Objective: To compare surgical and functional enucleation outcomes in real-world multicentre practice using high-power holmium laser (HP-HoLEP) and thulium fiber laser enucleation of the prostate (ThuFLEP) for different prostate sizes. Design, setting, and participants: The study included 4216 patients who underwent HP-HoLEP or ThuFLEP at eight centers in seven countries between 2020 and 2022. Exclusion criteria were previous urethral or prostatic surgery, radiotherapy, or concomitant surgery. Outcome measurements and statistical analysis: To adjust for the bias arising from different characteristics at baseline, propensity score matching (PSM) was used to identify 563 matched patients in each cohort. Outcomes included the incidence of postoperative incontinence, early complications (30-d), and delayed complications, and results for the International Prostate Symptom Score (IPSS), quality of life (QoL), maximum flow rate (Qmax), and postvoid residual volume (PVR). Results and limitations: After PSM, 563 patients in each arm were included. Total operative time was similar between the arms, but enucleation and morcellation times were significantly longer for ThuFLEP. The rate of postoperative acute urinary retention was higher in the ThuFLEP arm (3.6% vs 0.9%; p = 0.005), but the 30-d readmission rate was higher in the HP-HoLEP arm (22% vs 8%; p = 0.016). There was no difference in postoperative incontinence rates (HP-HoLEP:19.7%, ThuFLEP:16.0%; p = 0.120). Rates of other early and delayed complications were low and comparable between the arms. The ThuFLEP group had higher Qmax (p < 0.001) and lower PVR (p < 0.001) than the HP-HoLEP group at 1-yr follow-up. The study is limited by its retrospective nature. Conclusions: This real-world study shows that early and delayed outcomes of enucleation with ThuFLEP are comparable to those with HP-HoLEP, with similar improvements in micturition parameters and IPSS. Patient summary: As lasers become readily available for the treatment of enlarged prostates causing urinary bother, urologists should focus on performing good anatomic removal of prostate tissue, with the choice of laser not as important for good outcomes. Patients should be counseled about long-term complications, even when the procedure is being performed by an experienced surgeon.
AB - Background: Different lasers have been developed for treatment of benign prostatic hyperplasia, with no definitively superior technique identified to date. Objective: To compare surgical and functional enucleation outcomes in real-world multicentre practice using high-power holmium laser (HP-HoLEP) and thulium fiber laser enucleation of the prostate (ThuFLEP) for different prostate sizes. Design, setting, and participants: The study included 4216 patients who underwent HP-HoLEP or ThuFLEP at eight centers in seven countries between 2020 and 2022. Exclusion criteria were previous urethral or prostatic surgery, radiotherapy, or concomitant surgery. Outcome measurements and statistical analysis: To adjust for the bias arising from different characteristics at baseline, propensity score matching (PSM) was used to identify 563 matched patients in each cohort. Outcomes included the incidence of postoperative incontinence, early complications (30-d), and delayed complications, and results for the International Prostate Symptom Score (IPSS), quality of life (QoL), maximum flow rate (Qmax), and postvoid residual volume (PVR). Results and limitations: After PSM, 563 patients in each arm were included. Total operative time was similar between the arms, but enucleation and morcellation times were significantly longer for ThuFLEP. The rate of postoperative acute urinary retention was higher in the ThuFLEP arm (3.6% vs 0.9%; p = 0.005), but the 30-d readmission rate was higher in the HP-HoLEP arm (22% vs 8%; p = 0.016). There was no difference in postoperative incontinence rates (HP-HoLEP:19.7%, ThuFLEP:16.0%; p = 0.120). Rates of other early and delayed complications were low and comparable between the arms. The ThuFLEP group had higher Qmax (p < 0.001) and lower PVR (p < 0.001) than the HP-HoLEP group at 1-yr follow-up. The study is limited by its retrospective nature. Conclusions: This real-world study shows that early and delayed outcomes of enucleation with ThuFLEP are comparable to those with HP-HoLEP, with similar improvements in micturition parameters and IPSS. Patient summary: As lasers become readily available for the treatment of enlarged prostates causing urinary bother, urologists should focus on performing good anatomic removal of prostate tissue, with the choice of laser not as important for good outcomes. Patients should be counseled about long-term complications, even when the procedure is being performed by an experienced surgeon.
KW - Benign prostatic hyperplasia
KW - Endoscopic enucleation of the prostate
KW - Holmium laser
KW - Laser therapy
KW - Thulium fiber laser
UR - http://www.scopus.com/inward/record.url?scp=85166347609&partnerID=8YFLogxK
U2 - 10.1016/j.euf.2023.06.009
DO - 10.1016/j.euf.2023.06.009
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 37414615
AN - SCOPUS:85166347609
SN - 2405-4569
VL - 10
SP - 182
EP - 188
JO - European Urology Focus
JF - European Urology Focus
IS - 1
ER -